Cost Effectiveness Analysis [ocac]    
strategies [menp]    
Hepatitis C screening [topp]    
French [popg]    
Blood [tisu]    
Recipient [humn]    
Background [cnce]    
Context [fndg]    
Health Resources [idcn]    
Medical [ftcn]    
practice [menp]    
Aim [idcn]    
studies [mnob]    
To [qlco]    
Compare [acty]    
Cost Effectiveness [qnco]    
Different [qlco]    
screen [hlca]    
strategies [menp]    
Hepatitis C virus [virs]    
Blood [tisu]    
Recipient [humn]    
Method [inpr]    
Cost Effectiveness [qnco]    
Model [inpr]    
used [fndg]    
To [qlco]    
Test [lbpr]    
Nine [qnco]    
screen [hlca]    
strategies [menp]    
Three [qnco]    
Survival [acty]    
Categories [inpr]    
Three [qnco]    
Model [inpr]    
used [fndg]    
Three [qnco]    
Method [inpr]    
Follow-up [fndg]    
Margin [spco]    
Cost Effectiveness [qnco]    
Ratio [qnco]    
Estimate [qnco]    
To [qlco]    
Compare [acty]    
screen [hlca]    
strategies [menp]    
Result [ftcn]    
Hepatitis C virus [virs]    
Serologic [lbpr]    
Enzyme-Linked Immunosorbent Assay [lbpr]    
confirm [qlco]    
detect [topp]    
RNA virus [virs]    
To [qlco]    
Dominance [ftcn]    
strategies [menp]    
Margin [spco]    
Cost Effectiveness [qnco]    
Ratio [qnco]    
Subject [grup]    
/40 [tmco]    
low [qlco]    
*Volume [qnco]    
Transfused [topp]    
patient [podg]    
+2 [qnco]    
French Franc [qnco]    
Life [idcn]    
year [tmco]    
Gain [qnco]    
Sensitive [qnco]    
Analysis [lbpr]    
Show [inpr]    
Margin [spco]    
Cost Effectiveness [qnco]    
Ratio [qnco]    
Prevalence [qnco]    
Survival Rate [qnco]    
Lower [spco]    
Margin [spco]    
Cost Effectiveness [qnco]    
Ratio [qnco]    
Estimate [qnco]    
French Franc [qnco]    
Life [idcn]    
year [tmco]    
Gain [qnco]    
Conclusion [idcn]    
This [euka]    
studies [mnob]    
Show [inpr]    
High [qlco]    
Cost [qnco]    
Few [qnco]    
Life [idcn]    
year [tmco]    
Gain [qnco]    
Dominance [ftcn]    
strategies [menp]    
More [ftcn]    
Favorable [qlco]    
Risk [qlco]    
Group [idcn]    
New [tmco]    
studies [lbpr]    
carried [acty]    
Out [spco]    
New [tmco]    
screen [hlca]    
Therapeutic [topp]    
strategies [menp]    
